Bexarotene - ReXceptor

Drug Profile

Bexarotene - ReXceptor

Latest Information Update: 24 Sep 2015

Price : $50

At a glance

  • Originator Ligand Pharmaceuticals
  • Developer Cleveland Clinic
  • Class Antineoplastics; Benzoic acids; Naphthalenes; Retinoids; Small molecules
  • Mechanism of Action Peroxisome proliferator-activated receptor agonists; Protein synthesis inhibitors; Retinoic acid receptor agonists; Retinoid X receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Alzheimer's disease

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 01 Dec 2014 The Cleveland Clinic, Ohio, completes the BEAT-AD phase II trial in Alzheimer's disease (In the elderly) in USA (NCT01782742)
  • 11 Feb 2014 ReXceptor plans a phase I trial in Healthy volunteers in USA (NCT02061878)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top